GlassScriptPhysician profile
Claire Ellender
NPI 1033223599
$3,580.68
in general payments reported to CMS, 2019-2025
30 companies · $870 in 2025
The $870 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $219 · 2023: $691 · 2024: $1,205 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Travel and Lodging: $701 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.97 |
| Travel and Lodging | $701.41 |
| Education | $101.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $818.40 | 2025 | |
| Abbvie INC. | $538.33 | 2021-2024 | |
| Novo Nordisk INC | $434.91 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $404.27 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $244.90 | 2022-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $176.46 | 2024 | Mounjaro, Zepbound, Jardiance |
| Edwards Lifesciences Corporation | $148.79 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $103.75 | 2021-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.35 | 2024 | Xifaxan |
| Hologic Sales and Service, LLC | $63.93 | 2022 | |
| Amgen INC. | $60.41 | 2021-2024 | Evenity, Prolia |
| Biohaven Pharmaceuticals, INC. | $56.16 | 2021 | |
| Sanofi-Aventis U.S. LLC | $52.47 | 2023-2024 | |
| Genentech USA, INC. | $45.83 | 2021-2022 | |
| Abiomed | $35.46 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $32.96 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $31.02 | 2022-2024 | Rexulti |
| Dexcom, INC. | $30.78 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.84 | 2024 | Caplyta |
| Sumitomo Pharma America, INC. | $26.68 | 2024 | Gemtesa |
| Eisai INC. | $23.90 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.61 | 2024 | Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2024 | Trintellix |
| Antares Pharma, INC. | $21.12 | 2024 | Xyosted |
| Pfizer INC. | $16.90 | 2024 | |
| Inspire Medical Systems, INC. | $16.32 | 2025 | Inspire |
| Mylan Specialty L.P. | $16.26 | 2024 | Yupelri |
| Hikma Pharmaceuticals USA | $15.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.86 | 2024 | Zoryve |
| Allergan, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Ellender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.